it's not a large cap and in a downtrend; so it will get attention from r/wallstreetbets
HZNP announced its intent to acquire Viela Bio which is a biotech company with a mid-stage biologics pipeline in auto-immune and inflammatory conditions. Viela Bio recently (June 2020) launched Uplinza (anti-CD19 antibody) in the US for NMOSD (rare ocular disorder). Viela Bio's platform of three unique biologic molecules with 9 potential indications as drivers for...
According to Wells Fargo Advisors, "BAX: OMCL Would Be An Excellent Fit ... OMCL would bring better IT integration and an expanded set of hospital relationships as Baxter launches a new infusion pump next year. OMCL might also be able to finally realize its vision of a stronger international business (9% of total revenue) with the help of Baxter’s infrastructure....
a team less than 20 works on the development of recombinant proteins for the treatment of gastrointestinal diseases.
a clinical-stage company focused on developing & commercialising oncology & rare diseases treatments.
any pullbacks are additional short-term trades
Microsoft is joining forces with Cruise, the self-driving subsidiary of General Motors, to help speed up the commercialization of autonomous vehicles. The software giant is also chipping in on a new equity investment of $2 billion for Cruise, along with previous investors Honda and GM, bringing the AV company’s valuation up to a whopping $30 billion.
Triterras is a leading fintech company unlocking new opportunities in global trade and trade finance. According to Linkedin, it has 20+ employees! Very High Risk!
Is its fitness app a hit or just hitting a wall?
I'm attractive to its options' premium.
$10 is an easy target! $35 is what I wish!
I'm trading it to my favorite moving average in its daily chart.
It focuses on rare diseases -> high margin. Linkedin illustrates more than 200 employees working for this smallcap.
According to its website, DARE pipeline focuses on product candidates with first-in-category potential for women requiring or desiring new therapies in contraception, vaginal health, sexual health and fertility. It has 18 employees listed in Linkedin.
MU and TSM set the tone for other semiconductors' earning.
notes from BoA Global Research: "In order for the split-off to close fully subscribed, DD needs nearly 197mn shares to tender. Much of this volume will come via merger arbitrage investors, which we estimate may have already purchased 170mn shares, the bulk of which has come since the formal tender launch on 31 Dec ‘20. Of course the deal could be oversubscribed,...
Notes from BoA: "4Q20 Fintepla sales of $8.1mn are strong despite REMS ZGNX pre-announced 4Q20 Fintepla sales of $8.1mn above our ($5.5mn) and Cons. ($5.4mn) estimates. As of December 31st, 2020, 492 prescribers had completed the Risk Evaluation and litigation Strategy (REMS) program, and more than 550 pts had been prescribed Fintepla and enrolled in the REMS...
This stock is underperforming the market and its sector; so I want to see how it trades on a good news before being an aggressive bull.